PTC THERAPEUTICS INTERNATIONAL LIMITED

Ptc Therapeutics International Limited is a global biopharmaceutical company dedicated to discovering, developing and commercialising clinically differentiated medicines for children and adults living with serious, high-unmet-need diseases. By harnessing cutting-edge science - from splicing modulation to targeting inflammation and ferroptosis pathways - PTC creates therapies that address the underlying causes of rare conditions, transforming patients' lives.

The company's portfolio already includes several world-first approvals, such as the inaugural treatment for Duchenne muscular dystrophy, the first gene therapy delivered directly into the brain, and the first small-molecule splicing modifier. Its current therapeutic focus spans aromatic L-amino-acid decarboxylase deficiency, Duchenne muscular dystrophy, phenylketonuria, and Friedreich's ataxia, with a diversified pipeline that continues to address significant gaps in care. PTC also supports clinical-trial research, provides resources for healthcare professionals, patients and caregivers, and maintains an active newsroom that highlights breakthroughs and patient stories.

Driven by a passion for patients and a commitment to innovative science, PTC invites talented individuals to join its "One PTC" culture, where challenging the status-quo is part of everyday work.